GB2494851A — Plasma kallikrein inhibitors
Assigned to Kalvista Pharmaceuticals Ltd · Expires 2013-03-27 · 13y expired
What this patent protects
Benzylamine derivatives (or dipeptide derivatives) of formula (I) may be inhibitors of plasma kallikrein. R1 - R8 and R10 are H or a substituent (or R4, R5 and their connecting atoms combine to form a 5- or 6-membered azacycloalkyl); R9 is aryl or heteroaryl; the substituents are…
USPTO Abstract
Benzylamine derivatives (or dipeptide derivatives) of formula (I) may be inhibitors of plasma kallikrein. R1 - R8 and R10 are H or a substituent (or R4, R5 and their connecting atoms combine to form a 5- or 6-membered azacycloalkyl); R9 is aryl or heteroaryl; the substituents are as further defined in claim 1. The benzylamine derivatives may be useful for the treatment of impaired visual acuity, diabetic retinopathy or diabetic macular oedema. The benzylamine derivative may be (S)-N-(4-aminomethyl-benzyl)-2-[(R)-3-(4-ethoxy-phenyl)-2-propionylamino-propionylamino]-3-phenyl-propionamide, (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide or (2S, 3R)-1-[(R)-3-(4-ethoxy-phenyl)-2-propionylamino-propionyl]-3-phenyl-pyrrolidine-2-carboxylic acid 4-aminomethyl-benzylamide.
Drugs covered by this patent
- Ekterly (SEBETRALSTAT) · Kalvista
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.